ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen Essentiële trombocytose (ET) Richtlijnen en literatuur

Richtlijnen

Klik HIER voor de richtlijn 'Essentiële trombocytose' van de HOVON CML-MPN werkgroep.

Literatuur

  1. Alvarez-Larrán A et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica 2016 101(8): 926–931
  2. Arber DA et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016 127:2391-2405
  3. Khoury et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic dendritic neoplasms - Leukemia 2022 - 36: 1703-1719
  4. Barbui T et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012 120:5128–33
  5. Barbui T et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018 May;32(5):1057-69
  6. Emanuel RM et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012 Nov 20;30(33):4098-103
  7. Gisslinger H et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood, 2015 126(15): 1762-9
  8. Harrison CN et al. Myeloproliferative disorders in pregnancy. Hematol Oncol Clin North Am. 2011 25:261-75
  9. Harrison CN et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxy­carbamide. Blood 2017 130(17):1889-97
  10. Hamulyak EN et al. A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms. Blood Advances 2021 5(1):113-121
  11. Racca C et al. Aspirin intake in the morning is associated with suboptimal platelet inhibition, as measured by serum Thromboxane B2, during infarctprone early-morning hours. Platelets 2019 30(7):871-77
  12. Riva N et al. Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res. 2012 Oct;130 Suppl 1:S1-3
  13. Rocca B et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood 2020 136(2): 171-82
  14. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition. World Health Organiszation 2017
  15. Tiede A et al. How I treat the acquired von Willebrand syndrome. Blood 2011 117(25):6777-6785

 

Ga terug naar de ET homepage of lees meer over ET:

Ga terug naar de algemene homepage Behandelprotocollen.